{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"uniQure N.V."},"Symbol":{"label":"Symbol","value":"QURE"},"Address":{"label":"Address","value":"PAASHEUVELWEG 25, AMSTERDAM, 1105 BP, Netherlands"},"Phone":{"label":"Phone","value":"+31 202406000"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases."},"CompanyUrl":{"label":"Company Url","value":"https://www.uniqure.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Amin Abujoub","title":"Chief Technical Operations Officer"},{"name":"Matthew C. Kapusta","title":"Chief Executive Officer & Executive Director"},{"name":"Richard Porter","title":"Chief Business & Scientific Officer"},{"name":"Walid Abi-Saab","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}